Cargando…
Financial Toxicities Persist for Cancer Survivors Irrespective of Current Cancer Status: An Analysis of Medical Expenditure Panel Survey
This study estimates the out-of-pocket (OOP) expenditures for different cancer types among survivors with current versus no current cancer condition and across sex, which is understudied in the literature. This is a cross-sectional study of Medical Expenditure Panel Survey data for 2009–2018 where t...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9757609/ https://www.ncbi.nlm.nih.gov/pubmed/36531523 http://dx.doi.org/10.1158/2767-9764.CRC-22-0166 |
_version_ | 1784851856675045376 |
---|---|
author | Karim, Mohammad A. Talluri, Rajesh Shastri, Surendra S. Kum, Hye-Chung Shete, Sanjay |
author_facet | Karim, Mohammad A. Talluri, Rajesh Shastri, Surendra S. Kum, Hye-Chung Shete, Sanjay |
author_sort | Karim, Mohammad A. |
collection | PubMed |
description | This study estimates the out-of-pocket (OOP) expenditures for different cancer types among survivors with current versus no current cancer condition and across sex, which is understudied in the literature. This is a cross-sectional study of Medical Expenditure Panel Survey data for 2009–2018 where the primary outcome was the average per year OOP expenditure incurred by cancer survivors. Of 189,285 respondents, 15,010 (7.93%) were cancer survivors; among them, 46.28% had a current cancer condition. Average per year OOP expenditure for female survivors with a current condition of breast cancer ($1,730), lung cancer ($1,679), colon cancer ($1,595), melanoma ($1,783), non–Hodgkin lymphoma ($1,656), nonmelanoma/other skin cancer (NMSC, $2,118) and two or more cancers ($2,310) were significantly higher than that of women with no history of cancer ($853, all P < 0.05). Similarly, average per year OOP expenditure for male survivors with a current condition of prostate cancer ($1,457), lung cancer ($1,131), colon cancer ($1,471), melanoma ($1,474), non–Hodgkin lymphoma ($1,653), NMSC ($1,789), and bladder cancer ($2,157) were significantly higher compared with the men with no history of cancer ($621, all P < 0.05). These differences persisted in survivors with no current cancer condition for breast cancer among women; prostate, lung, colon, and bladder cancer among men; and melanoma, NMSC, and two or more cancers among both sexes. OOP expenditure varied across cancer types and by sex for survivors with and without a current cancer condition. These findings highlight the need for targeted interventions for cancer survivors. SIGNIFICANCE: Our study found that OOP expenditures among survivors with a current cancer condition for several cancers were significantly higher than that of individuals without a cancer history. These differences persisted in female with breast cancer; male with prostate, lung, colon, and bladder cancer; and survivors of both sexes with melanoma, and NMSC/other skin cancer, even after there was no current cancer condition. |
format | Online Article Text |
id | pubmed-9757609 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-97576092022-12-16 Financial Toxicities Persist for Cancer Survivors Irrespective of Current Cancer Status: An Analysis of Medical Expenditure Panel Survey Karim, Mohammad A. Talluri, Rajesh Shastri, Surendra S. Kum, Hye-Chung Shete, Sanjay Cancer Res Commun Research Article This study estimates the out-of-pocket (OOP) expenditures for different cancer types among survivors with current versus no current cancer condition and across sex, which is understudied in the literature. This is a cross-sectional study of Medical Expenditure Panel Survey data for 2009–2018 where the primary outcome was the average per year OOP expenditure incurred by cancer survivors. Of 189,285 respondents, 15,010 (7.93%) were cancer survivors; among them, 46.28% had a current cancer condition. Average per year OOP expenditure for female survivors with a current condition of breast cancer ($1,730), lung cancer ($1,679), colon cancer ($1,595), melanoma ($1,783), non–Hodgkin lymphoma ($1,656), nonmelanoma/other skin cancer (NMSC, $2,118) and two or more cancers ($2,310) were significantly higher than that of women with no history of cancer ($853, all P < 0.05). Similarly, average per year OOP expenditure for male survivors with a current condition of prostate cancer ($1,457), lung cancer ($1,131), colon cancer ($1,471), melanoma ($1,474), non–Hodgkin lymphoma ($1,653), NMSC ($1,789), and bladder cancer ($2,157) were significantly higher compared with the men with no history of cancer ($621, all P < 0.05). These differences persisted in survivors with no current cancer condition for breast cancer among women; prostate, lung, colon, and bladder cancer among men; and melanoma, NMSC, and two or more cancers among both sexes. OOP expenditure varied across cancer types and by sex for survivors with and without a current cancer condition. These findings highlight the need for targeted interventions for cancer survivors. SIGNIFICANCE: Our study found that OOP expenditures among survivors with a current cancer condition for several cancers were significantly higher than that of individuals without a cancer history. These differences persisted in female with breast cancer; male with prostate, lung, colon, and bladder cancer; and survivors of both sexes with melanoma, and NMSC/other skin cancer, even after there was no current cancer condition. American Association for Cancer Research 2022-10-05 /pmc/articles/PMC9757609/ /pubmed/36531523 http://dx.doi.org/10.1158/2767-9764.CRC-22-0166 Text en © 2022 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by/4.0/This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. |
spellingShingle | Research Article Karim, Mohammad A. Talluri, Rajesh Shastri, Surendra S. Kum, Hye-Chung Shete, Sanjay Financial Toxicities Persist for Cancer Survivors Irrespective of Current Cancer Status: An Analysis of Medical Expenditure Panel Survey |
title | Financial Toxicities Persist for Cancer Survivors Irrespective of Current Cancer Status: An Analysis of Medical Expenditure Panel Survey |
title_full | Financial Toxicities Persist for Cancer Survivors Irrespective of Current Cancer Status: An Analysis of Medical Expenditure Panel Survey |
title_fullStr | Financial Toxicities Persist for Cancer Survivors Irrespective of Current Cancer Status: An Analysis of Medical Expenditure Panel Survey |
title_full_unstemmed | Financial Toxicities Persist for Cancer Survivors Irrespective of Current Cancer Status: An Analysis of Medical Expenditure Panel Survey |
title_short | Financial Toxicities Persist for Cancer Survivors Irrespective of Current Cancer Status: An Analysis of Medical Expenditure Panel Survey |
title_sort | financial toxicities persist for cancer survivors irrespective of current cancer status: an analysis of medical expenditure panel survey |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9757609/ https://www.ncbi.nlm.nih.gov/pubmed/36531523 http://dx.doi.org/10.1158/2767-9764.CRC-22-0166 |
work_keys_str_mv | AT karimmohammada financialtoxicitiespersistforcancersurvivorsirrespectiveofcurrentcancerstatusananalysisofmedicalexpenditurepanelsurvey AT tallurirajesh financialtoxicitiespersistforcancersurvivorsirrespectiveofcurrentcancerstatusananalysisofmedicalexpenditurepanelsurvey AT shastrisurendras financialtoxicitiespersistforcancersurvivorsirrespectiveofcurrentcancerstatusananalysisofmedicalexpenditurepanelsurvey AT kumhyechung financialtoxicitiespersistforcancersurvivorsirrespectiveofcurrentcancerstatusananalysisofmedicalexpenditurepanelsurvey AT shetesanjay financialtoxicitiespersistforcancersurvivorsirrespectiveofcurrentcancerstatusananalysisofmedicalexpenditurepanelsurvey |